Product IntroductionBioactivity英文名:
CGP60474描述: CGP60474 是一种高效的抗内毒素药物,抑制细胞周期蛋白依赖激酶(CDK) ,抑制 CDK1/B、CDK2/E、CDK2/a、CDK4/D、CDK5/p25、CDK7/H 和 CDK9/T 的IC50分别为 26、3、4、216、10、200 和 13 nM。它是选择性和 ATP 竞争性PKC 抑制剂。
体外活性: The IC50 values are 26, 3, 4, 216, 10, 200 and 13 nM for CDK1/CyclinB, CDK2/CyclinE, CDK2/CyclinA, CDK5/p25, CDK7/CyclinH, CDK4/CyclinD and CDK9/cycT, respectively[4].
体内活性: 在LPS内毒素血症模型中,CGP60474(10mg/kg;i.p.)抑制了IL-6水平并提高了存活率[3]。
存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
溶解度: DMSO : 50 mg/mL (140.52 mM)
H2O : < 0.1 mg/mL (insoluble)
关键字:
inhibit |
endotoxemic |
CGP-60474 |
Cyclin dependent kinase |
LPS |
PKC |
Inhibitor |
Protein kinase C |
CDK |
CGP60474 |
selective |
survival |
ATP-competitive |
IL-6 level |
CGP 60474相关产品:
Bucillamine |
Jaceidin |
AZD4547 |
VEGFR-2-IN-33 |
KI8751 |
CGP77675 |
(Z)-Semaxinib |
PD173074 |
Tyrosine kinase-IN-1 |
Ripretinib相关库:
Angiogenesis related Compound Library |
Anti-Cancer Compound Library |
Membrane Protein-targeted Compound Library |
Bioactive Compounds Library Max |
Anti-Lung Cancer Compound Library |
Inhibitor Library |
Kinase Inhibitor Library |
Epigenetics Compound Library |
Tyrosine Kinase Inhibitor Library |
TGF-beta/Smad Compound Library